Increase of Bcl-2 protein in neuronal dendritic processes of cerebral cortex and hippocampus by the antiparkinsonian drugs, talipexole and pramipexole

• Published in: Brain research Vol. 872; no. 1; pp. 236 - 241
• Main Authors: Takata, Kazuyuki, Kitamura, Yoshihisa, Kakimura, Jun-ichi, Kohno, Yasuko, Taniguchi, Takashi
• Format: Journal Article
• Language: English
• Published: London Elsevier B.V 28.07.2000; Amsterdam Elsevier; New York, NY
• Subjects: Animals; Anticonvulsants. Antiepileptics. Antiparkinson agents; Antiparkinson Agents - administration & dosage; Azepines - administration & dosage; Bcl-2; Benzothiazoles; Biological and medical sciences; Cell Membrane - metabolism; Cerebral Cortex - drug effects; Cerebral Cortex - metabolism; Cytosol - metabolism; Dendrites - metabolism; Dopamine Agonists - administration & dosage; Drug Administration Schedule; Hippocampus - drug effects; Hippocampus - metabolism; Immunoblotting; Injections, Intraperitoneal; Male; Medical sciences; Neuropharmacology; Pharmacology. Drug treatments; Pramipexole; Proto-Oncogene Proteins c-bcl-2 - metabolism; Rats; Rats, Wistar; Regeneration; Talipexole; Thiazoles - administration & dosage; Bcl-2; Regeneration; Development and regeneration; Talipexole; Pramipexole; Cerebral cortex; Rat; Rodentia; Central nervous system; Neuroprotective agent; Gene expression; Antiparkinson agent; Dendrite; Neurotrophic factor; Vertebrata; Mammalia; Animal; Hippocampus; Brain (vertebrata)
• ISSN: 0006-8993; 1872-6240
• DOI: 10.1016/S0006-8993(00)02493-8

Treatment of rats for 4 days with the antiparkinsonian drugs, talipexole and pramipexole, markedly increased Bcl-2 immunoreactivity in neuronal dendritic processes in both cerebral cortex and hippocampus, but treatment for 1 day with either of these drugs did not. Repeated administration of talipexole or pramipexole may have neuroprotective effect in neurodegenerative disorders.